An interventional study of Prostate stimulator in Sexual Dysfunction, Erectile Dysfunction and Delayed Ejaculation, sponsored by Stanford University. Recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Stanford University · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 180 studies in Erectile Dysfunction with a site in United States — 26 open to participants now, 31 under way, 3 of them phase 3. Erectile Dysfunction · United States.
Among the 180 studies in Erectile Dysfunction with a site in United States, this one is the 131st largest by planned enrollment of the 164 interventional ones that give a count, is one of 10 that started in 2024, is one of 62 with no phase, reaches primary completion later than 17 of the 30 other live ones, and was the 149th registered.
702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.
Browse Erectile Dysfunction studies →26 of the 180 studies in Erectile Dysfunction with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18+ · Men only
The Methodist Hospital Research Institute · Sites in United States
Ages 40–70 · Men only
Rigicon, Inc. · Sites in United States
Ages 22+ · Men only
J. Peter Rubin, MD · Sites in United States
Ages 18+ · Men only
University of California, Irvine · Sites in United States
Ages 18+ · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
180 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 26 · Phase 3 32 · Phase 4 25
First in 1988; this study’s year is marked. 10 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 70 across 551 interventional studies indexed under Erectile Dysfunction.
Median enrollment 75 across the 164 interventional studies, 93 across the 16 observational. Of the 128 that completed or were terminated, 51 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
93 of 180 have an industry lead sponsor. The 10 most frequent:
Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.
Stanford University has 3 studies filed under Erectile Dysfunction — fewer than ten, so there is no comparison to draw.
14 of the studies in Erectile Dysfunction with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03701581Phase 3John Elfar4-aminopyridine Treatment for Nerve Injury | 2027-07 |
| NCT06945315Phase 3Icahn School of Medicine at Mount SinaiSAFE Nerve Sparing Guided by Micro-ultrasound (MUS) | 2027-07-14 |
| NCT06065436Mayo ClinicConcurrent Low Intensity Shockwave Therapy on Collagenase Clostridium Histolyticum for Peyronie's Disease | 2026-12 |
| NCT05868668The Cleveland ClinicEfficacy of Low-intensity Shockwave vs Radial Wave for Treatment of Erectile Dysfunction and Pelvic Pain | 2026-12 |
| NCT02706561Memorial Sloan Kettering Cancer CenterHelping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery | 2026-12 |
Add all 14 to your calendar (.ics) → With an account.
Among the 180 studies in Erectile Dysfunction with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to use a device to stimulate the prostate with a goal of helping improve symptoms in men with sexual dysfunction.
The purpose of the study is to use a device to stimulate the prostate. The goal of this is to help men with sexual dysfunction. Sexual dysfunction can include conditions like delayed ejaculation (e.g.takes more than 21 minutes to climax) and can hopefully assist them in achieving faster time to ejaculation (e.g. closer to the median of 5.4 minutes in a "normal" individual) along with erectile dysfunction (e.g. the inability to achieve and sustain an erection).
702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.
This study's planned enrollment of 15 is below the median of 70 across 551 interventional studies indexed under Erectile Dysfunction.
Browse Erectile Dysfunction studies →Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.
Compared within Erectile Dysfunction, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sexual Dysfunction, Physiological. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will be asked to use our prostate stimulation device.
Device: Prostate stimulator
Prostate stimulation device for sexual dysfunction
change in modified International Index of Erectile Dysfunction score
score 0 to 30 with higher score meaning better erectile function
Time frame: baseline and up to 1 month post-baseline
Started Apr 2024 (actual). Primary completion is estimated for Jun 2027, 37 months after the start.
Of 115 non-industry interventional studies with no phase under Erectile Dysfunction, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's planned 37 months is above that.
Counting every sponsor, half of 137 studies reached it within 32 months; a quarter within 14 and three quarters within 52.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Jun 2026 → Jun 2027 and completion Jun 2026 → Jun 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.